 |
|
Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease
In-Jeong Cho, Seok-Min Kang
Kidney Res Clin Pract. 2021;40(4):555-565. Published online 2021 Nov 22 DOI: https://doi.org/10.23876/j.krcp.21.900
|
|
Citations to this article as recorded by
 Efficacy and safety of angiotensin receptor–neprilysin inhibition in heart failure patients with end‐stage kidney disease on maintenance dialysis: A systematic review and meta‐analysis
Dung Viet Nguyen, Thanh Ngoc Le, Binh Quang Truong, Hoai Thi Thu Nguyen
European Journal of Heart Failure.2025; 27(1): 72. CrossRef Efficacy and safety of sacubitril-valsartan in hypertension patients with end-stage kidney disease on maintenance dialysis: a meta-analysis
Dung Viet Nguyen, Giang Thai Pham, Son Nguyen Pham, Hoai Thi Thu Nguyen
Journal of Hypertension.2025; 43(4): 557. CrossRef Sacubitril/valsartan improves all-cause mortality in heart failure patients with reduced ejection fraction and chronic kidney disease
Wei-Chieh Lee, Ting-Wei Liao, Tien-Yu Chen, Hsiu-Yu Fang, Yen-Nan Fang, Huang-Chung Chen, Yu-Sheng Lin, Shang-Hung Chang, Mien-Cheng Chen
Cardiovascular Drugs and Therapy.2024; 38(3): 505. CrossRef Hypertrophic Cardiomyopathy and Chronic Kidney Disease: An Updated Review
Sheefah Dhuny, Henry Wu, Manova David, Rajkumar Chinnadurai
Cardiogenetics.2024; 14(1): 26. CrossRef The role of sacubitril/valsartan in abnormal renal function patients combined with heart failure: a meta-analysis and systematic analysis
Xinyue Yang, Jingjing Jin, Meijuan Cheng, Jinsheng Xu, Yaling Bai
Renal Failure.2024;[Epub] CrossRef Management of patients with heart failure and chronic kidney disease
Lingling Wu, Mario Rodriguez, Karim El Hachem, W. H. Wilson Tang, Chayakrit Krittanawong
Heart Failure Reviews.2024; 29(5): 989. CrossRef Impact of Sodium‐Glucose Co‐Transporter‐2 Inhibitors on Exercise‐Induced Pulmonary Hypertension
Taijyu Satoh, Nobuhiro Yaoita, Satoshi Higuchi, Kotaro Nochioka, Saori Yamamoto, Haruka Sato, Shunsuke Tatebe, Kaito Yamada, Yusuke Yamada, Kohei Komaru, Naoki Chiba, Yuki Sarashina, Ryuichi Mori, Mitsuru Nakada, Hideka Hayashi, Hideaki Suzuki, Hiroyuki T
Pulmonary Circulation.2024;[Epub] CrossRef Sakubitril valsartan’ın deneysel havyan modellerindeki yeri
Ali DUYGU, Emine GAZİ
Troia Medical Journal.2023;[Epub] CrossRef Renin–angiotensin–aldosterone pathway modulators in chronic kidney disease: A comparative review
Saeed Alshahrani
Frontiers in Pharmacology.2023;[Epub] CrossRef Efficacy and safety of vericiguat in heart failure: a meta-analysis
Jianhua Ma, Sheng Guo, Huan Jiang, Bo Li
Journal of International Medical Research.2023;[Epub] CrossRef The efficacy and safety of sacubitril/valsartan in chronic kidney disease: a systematic review and meta-analysis
Wei Zhou, Xinyue Yang, JingJing Jin, Meijuan Cheng, Yajing Li, Yaling Bai, Jinsheng Xu
International Urology and Nephrology.2023; 56(1): 181. CrossRef Initiation, Treatment Response Evaluation, and Safety Monitoring of Angiotensin Receptor/Neprilysin Inhibitors (Sacubitril/Valsartan) in the Management of Heart Failure in India: An Expert Group Recommendations
Uday M. Jadhav, V. K. Chopra, S. Ray, A. Oomman
Journal of Indian College of Cardiology.2023; 13(4): 141. CrossRef Efficacy and Dosage Pattern of Sacubitril/Valsartan in Chinese Heart Failure with Reduced Ejection Fraction Patients
Iokfai Cheang, Shi Shi, Xinyi Lu, Shengen Liao, Xu Zhu, Xi Su, Qi Lu, Jing Yuan, Dachun Xu, Min Zhang, Cuilian Dai, Jingfeng Wang, Fang Yuan, Yan Zhao, Jingmin Zhou, Xinli Li
Journal of Cardiovascular Translational Research.2022; 15(5): 1192. CrossRef
|